{
    "clinical_study": {
        "@rank": "56842", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1", 
                "arm_group_type": "Experimental", 
                "description": "Reference (insulin glargine) -Test1 (insulin glargine - new formulation), both dose will be adjusted individually to achieve the target glycemic goal"
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "arm_group_type": "Experimental", 
                "description": "Test1 - Reference , both dose will be adjusted individually to achieve the target glycemic goal"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      - To compare the 24-hour glycemic profile in continuous glucose monitoring (CGM) between a\n      new formulation of insulin glargine and Lantus at steady state\n\n      Secondary Objectives:\n\n        -  To compare the change of Fasting plasma glucose (FPG), Self-monitoring plasma glucose\n           (SMPG) and Postprandial Plasma Glucose (PPG) between the 2 treatments;\n\n        -  To compare the efficacy of the 2 treatments on glycemic control in glycemic parameters\n           (1,5-anhydroglucitol and hemoglobin A1c (glycosylated hemoglobin; HbA1c));\n\n        -  To compare the occurrence of hypoglycemia between the 2 treatments;\n\n        -  To assess the safety and tolerability of a new formulation of insulin glargine."
        }, 
        "brief_title": "Repeated Dose Study With a New Insulin Glargine Formulation and Lantus\u00ae on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type 1 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "detailed_description": {
            "textblock": "66 days"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  Japanese patients with Type 1 Diabetes Mellitus (T1DM) on treatment with basal-bolus\n             insulin;\n\n        Exclusion criteria:\n\n          -  Age < 20 years at written informed consent;\n\n          -  HbA1c < 6.5% or > 10.0% at screening\n\n          -  Diabetes mellitus (DM) other than T1DM;\n\n          -  Body Mass Index (BMI) > 35.0 kg/m2 at screening visit\n\n          -  Any contraindication to use of insulin glargine as defined in the Japanese Package\n             Insert\n\n          -  Hypoglycemia unawareness or history of metabolic acidosis, including hospitalization\n             for diabetic ketoacidosis during the 24 weeks prior to screening visit\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01676233", 
            "org_study_id": "PDY12335", 
            "secondary_id": "U1111-1129-3633"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2"
                ], 
                "description": "Pharmaceutical form: solution Route of administration: subcutaneous", 
                "intervention_name": "insulin glargine (HOE901)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2"
                ], 
                "description": "Pharmaceutical form: solution Route of administration: subcutaneous", 
                "intervention_name": "insulin glargine- new formulation  (HOE901)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kumamoto-Shi", 
                    "country": "Japan"
                }, 
                "name": "Investigational Site Number 392001"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, 2-treatment Crossover Study of a New Formulation of Insulin Glargine Comparing to Lantus\u00ae on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus on Treatment With Basal-bolus Insulin", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in 24-hour blood glucose profile measured by continuous glucose monitoring", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Day 28, Day 56"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01676233"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Hypoglycemia categorized by the definition of American Diabetes Association", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 56"
            }, 
            {
                "measure": "Change in fasting plasma glucose from baseline to each treatment end by treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 28, Day 56"
            }, 
            {
                "measure": "Change in self monitoring plasma glucose profile from baseline to each treatment end by treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 28, Day 56"
            }, 
            {
                "measure": "Change in HbA1c from baseline to each treatment end by treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 28, Day 56"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}